Advanced NSCLC Combination Treatment

Overall
Survival

In patients with advanced NSCLC with no EGFR, ALK, or ROS1 aberrations

Significantly EXTENDED SURVIVAL: Median OS of 21.9 months

with LIBTAYO + chemo* vs 13.0 months with chemo in EMPOWER-Lung 31,2

LIBTAYO + chemotherapy vs chemotherapy alone in EMPOWER-Lung 3 Overall Survival Data
  • *chemo=platinum-based chemotherapy
  • HR was based on stratified proportional hazards model.1
29%

Reduction of risk of death HR=0.71

(95% CI, 0.53-0.93),
P=0.0140

  • Number of deaths: 42% of patients (132 out of 312 patients) with LIBTAYO + chemotherapy and 53% of patients (82 out of 154 patients) with chemotherapy alone1
In patients with advanced NSCLC with no EGFR, ALK, ROS1 aberrations

Exploratory Analysis of Prespecified Histology Subgroup1,2

Limitations:

This is an exploratory analysis that was not powered to show a statistically significant difference in histologies. Firm conclusions
cannot be made based on these exploratory analyses.

Squamous
Median OS, months (95% CI)
LIBTAYO +
chemotherapy (n=133)
Chemotherapy
(n=67)
21.9 (15.6-NE)
13.8 (9.3-18.0)
HR (95% CI)*
0.56 (0.37-0.84)
  • Number of deaths (squamous): 43% of patients (57 out of 133) with LIBTAYO + chemotherapy and 58% of patients (39 out of 67) with chemotherapy alone
Nonsquamous
Median OS, months (95% CI)
LIBTAYO +
chemotherapy (n=179)
Chemotherapy
(n=87)
15.8 (13.7-NE)
13.0 (10.0-NE)
HR (95% CI)*
0.79 (0.54-1.14)
  • Due to the capping applied to the enrollment of patients with squamous histology, follow-up was shorter in the non-squamous subset versus the squamous subset.
  • Number of deaths (nonsquamous): 42% of patients (75 out of 179) with LIBTAYO + chemotherapy and 49% of patients (43 out of 87) with chemotherapy alone
  • *HR <1 favors LIBTAYO.
  • Advanced NSCLC is locally advanced NSCLC where patients are not candidates for surgical resection of definitive chemoradiation or metastatic NSCLC
  • CI=confidence interval; HR=hazard ratio; OS=overall survival.